VerImmune
Developer of immuno-oncology therapeutics that redirect pre-existing immune memory from prior infections or childhood vaccines to target cancer. The company’s platform uses virus-inspired particles to modify tumor cells to present viral antigens, enabling recruitment of memory CD8+ T cells and tumor cell killing. Activities include biomarker-driven patient selection, preclinical validation, regulatory interactions, and collaborative licensing and funding engagements.
Industries
Nr. of Employees
small (1-50)
Patents
Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-12528839-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-12344637-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11944677-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-11858964-B2
View DetailsConjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-11560408-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11285203-B2
View Details
Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-12528839-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-12344637-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11944677-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-11858964-B2
View DetailsConjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-11560408-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11285203-B2
View DetailsProducts
Virus-inspired particle (VIP) therapeutic platform
A platform of virus-inspired particles designed to modify tumor cells to present viral antigens and recruit pre-existing memory T cell responses for anticancer therapy.
AIR-ViP Technology Platform
VerImmune's AIR-ViP Technology Platform is designed to treat cancer by harnessing the body's immune memory against pathogens and childhood vaccines.
Anti-Tumor Immune Redirection
A breakthrough therapy platform that redirects pre-existing immune memory against pathogens or childhood vaccines to target and destroy cancer.
Virus-inspired particle (VIP) therapeutic platform
A platform of virus-inspired particles designed to modify tumor cells to present viral antigens and recruit pre-existing memory T cell responses for anticancer therapy.
AIR-ViP Technology Platform
VerImmune's AIR-ViP Technology Platform is designed to treat cancer by harnessing the body's immune memory against pathogens and childhood vaccines.
Anti-Tumor Immune Redirection
A breakthrough therapy platform that redirects pre-existing immune memory against pathogens or childhood vaccines to target and destroy cancer.
Services
Collaborative R&D agreements and licensing arrangements to develop and commercialize virus-inspired particle-based immunotherapies.
Collaborative R&D agreements and licensing arrangements to develop and commercialize virus-inspired particle-based immunotherapies.
Expertise Areas
- Immuno-oncology
- Nanoparticle-based therapeutics
- Biomarker development for patient selection
- Preclinical therapeutic development
Key Technologies
- Virus-inspired nanoparticle platform
- Immune memory redirection
- Biomarker assays for prior viral immunity
- Tumor antigen display engineering
News & Updates
Accepted into the NCI-sponsored nanotechnology characterization laboratory for particle evaluation and characterization support.
Announced a research collaboration to leverage the company’s immuno-oncology therapeutic platform.
Entered into an exclusive license and option agreement for the VIP platform in China with a regional partner.
Reported a positive pre-IND meeting with the U.S. Food and Drug Administration to discuss development plans.
Independent supportive preclinical data on anti-tumor immune redirection published in a peer-reviewed journal.
Awarded SBIR Phase II and related NSF funding to support platform advancement.
Accepted into the NCI-sponsored nanotechnology characterization laboratory for particle evaluation and characterization support.
Announced a research collaboration to leverage the company’s immuno-oncology therapeutic platform.
Entered into an exclusive license and option agreement for the VIP platform in China with a regional partner.
Reported a positive pre-IND meeting with the U.S. Food and Drug Administration to discuss development plans.
Independent supportive preclinical data on anti-tumor immune redirection published in a peer-reviewed journal.
Awarded SBIR Phase II and related NSF funding to support platform advancement.